17859-70-0

Usage

Uses

Used in Pharmaceutical Research:
(4-benzyloxycarbonylaminophenyl)-acetic acid is used as a building block for the development of novel pharmaceuticals, particularly in the synthesis of peptide-based drugs. Its ability to form peptide bonds makes it a valuable component in the creation of therapeutic compounds.
Used in Organic Synthesis:
(4-benzyloxycarbonylaminophenyl)-acetic acid is used as a reactant in organic synthesis, where it can be combined with other compounds to form a variety of chemical products.
Used as a Protecting Group in Peptide Synthesis:
(4-benzyloxycarbonylaminophenyl)-acetic acid is used as a protecting group in peptide synthesis, which helps to prevent unwanted side reactions during the synthesis process. This allows for the efficient and accurate production of desired peptide sequences.

Upstream product

• 501-53-1 benzyl chloroformate 
• 39552-81-3 methyl p-aminophenylacetate 
• 5438-70-0 ethyl (4-amino-3,5-dibromophenyl)acetate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 224577-12-2 ethyl N-4-<<(benzyloxy)carbonyl>amino>phenylacetate 
• 1197-55-3 4-aminophenylacetic acid 

Downstream Products

• 107966-12-1 (+/-)-N-(p-Aminophenylacetyl)-2-aminobutan 
• 69684-45-3 (+/-)-N-(p-Aminophenylacetyl)-1-(2-naphthyl)ethylamin 
• 69622-08-8 (R)-N-(p-Aminophenylacetyl)-1-phenyl-n-propylamin 
• 69622-11-3 (R)-N-(p-Aminophenylacetyl)-1-(2-naphthyl)ethylamin 
• 2792-95-2 4-Aminophenylacetic acid β-phenylisopropylamide 
• 31733-60-5 2-(4-aminophenyl)-N-(1-phenylethyl)acetamide 
• 149414-91-5 N-4-<<(benzyloxy)carbonyl>amino>phenylacetate N-hydroxysuccinimidyl ester 
• 1295538-68-9 C₁₈H₂₀N₂O₄ 
• 1258011-40-3 (4-chlorocarbonylmethylphenyl)carbamic acid benzyl ester 
• 419573-59-4 1-N-[4-(benzyloxycarbonylamino)phenylethanoyl]-6-O-[2-N-[4-(benzyloxycarbonyl)butylamino]ethylamino]-3,2',6'-tris(N-benzyloxycarbonyl)neamine 
• 738532-54-2 (+/-)-N-(p-Aminophenylacetyl)-1-phenyl-2-butylamin 

Relevant academic research and scientific papers

Design of a novel pyrrolidine scaffold utilized in the discovery of potent and selective human β3 adrenergic receptor agonists

A novel class of human β3-adrenergic receptor agonists was designed in effort to improve selectivity and metabolic stability versus previous disclosed β3-AR agonists. As observed, many of the β3-AR agonists seem to need th

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents

The synthesis and antiproliferative activity of a new series of rigid analogues of combretastatin A-4 are described which contain the 1,4-diaryl-2-azetidinone (β-lactam) ring system in place of the usual ethylene bridge present in the natural combretastatin stilbene products. These novel compounds are also substituted at position 3 of the β-lactam ring with an aryl ring. A number of analogues showed potent nanomolar activity in human MCF-7 and MDA-MB-231 breast cancer cell lines, displayed in vitro inhibition of tubulin polymerization, and did not cause significant cytotoxicity in normal murine breast epithelial cells. 4-(4-Methoxyaryl)-substituted compound 32, 4-(3-hydroxy-4-methoxyaryl)-substituted compounds 35 and 41, and the 3-(4-aminoaryl)-substituted compounds 46 and 47 displayed the most potent antiproliferative activity of the series. β-Lactam 41 in particular showed subnanomolar activity in MCF-7 breast cancer cells (IC50 = 0.8 nM) together with significant in vitro inhibition of tubulin polymerization and has been selected for further biochemical assessment. These novel β-lactam compounds are identified as potentially useful scaffolds for the further development of antitumor agents that target tubulin.

Design of novel antibiotics that bind to the ribosomal acyltransfer site

The structure of neamine bound to the A site of the bacterial ribosomal RNA was used in the design of novel aminoglycosides. The design took into account stereo and electronic contributions to interactions between RNA and aminoglycosides, as well as a ran

Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses

Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.